Mineralys Therapeutics (NASDAQ:MLYS) Announces Earnings Results, Beats Expectations By $0.02 EPS

Mineralys Therapeutics (NASDAQ:MLYS) announced its earnings results on Wednesday. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.02, Zacks reports.

Mineralys Therapeutics Trading Down 2.8 %

Shares of Mineralys Therapeutics stock traded down $0.29 on Thursday, reaching $10.34. 21,395 shares of the company were exchanged, compared to its average volume of 260,531. The company has a market capitalization of $514.42 million, a price-to-earnings ratio of -3.15 and a beta of 1.44. Mineralys Therapeutics has a one year low of $8.58 and a one year high of $16.91. The company has a 50-day moving average of $11.21 and a 200 day moving average of $12.03.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a report on Thursday.

Insider Buying and Selling

In other Mineralys Therapeutics news, CEO Jon Congleton sold 18,333 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $9.06, for a total transaction of $166,096.98. Following the transaction, the chief executive officer now owns 877,608 shares of the company’s stock, valued at $7,951,128.48. The trade was a 2.05 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.10, for a total transaction of $97,888.70. Following the transaction, the chief financial officer now directly owns 226,097 shares of the company’s stock, valued at approximately $2,057,482.70. This trade represents a 4.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 33.24% of the stock is owned by corporate insiders.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.